Home > Healthcare > Healthcare IT > Artificial Intelligence > real world evidence solutions market
Get a free sample of Real World Evidence Solutions Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Real World Evidence Solutions Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The real world evidence solutions industry is highly competitive and fragmented with the presence of large number of established players offering advanced and innovative solutions. Established market players are adopting product launches, and collaborations as their key growth strategies to gain competitive edge over their rivals.
Prominent players operating in the market is as mentioned below:
The drug development and approval segment will record USD 2.1 billion by 2032, primarily due to the crucial role RWE plays in enhancing the efficiency and effectiveness of clinical trials, providing valuable insights into drug performance in real-world settings.
Market size for real world evidence solutions had surpassed USD 1.9 billion during 2023 and could witness 15.7% CAGR between 2024 and 2032 owing to the expanding adoption of RWE in clinical research, increasing demand for evidence-based decision-making in healthcare, coupled with the need for cost-effective and efficient drug development processes.
Some of the leading real world evidence solutions industry players include Aetion, Inc., Cognizant Technology Solutions Corporation, Elevance Health, Inc., ICON plc., IQVIA Holdings Inc., Optum, Inc., Oracle Corporation, Parexel International Corporation, PerkinElmer Inc., SAS Institute Inc., among others.
North America real world evidence solutions industry will secure USD 2.6 billion by 2032, driven by the rising utilization of real-world evidence (RWE) solutions in clinical research, the presence of digital healthcare infrastructure facilitating the generation of ample real-time data, alongside increasing support from government and regulatory agencies like the US FDA for standardizing RWE solutions.